Modality | Indication | Targets | Stage | Company | Project No. | Detail | |
---|---|---|---|---|---|---|---|
1 | Development of mRNA.encoded NK cell engager for the treatment of relapsed/refractory B cell lymphoma | ||||||
Nucleic acid/Virus | B cell lymphoma | NK cell | Hit | De novo Biotherapeutics | RS-2023-00258675 | ||
2 | Candidate selection of a first.in.class RNA therapeuticfor the treatment of BRAF mutant pediatric brain tumors | ||||||
Nucleic acid/Virus | Pediatric brain tumor | BRAF | Candidate | Sovargen | RS-2023-00258484 |